摘要
目的:探究前列地尔辅助治疗急性脑梗死的临床效果。方法:选取2016年2月-2018年2月于本院确诊并收入院治疗的92例急性脑梗死患者。按照随机数字表法将其分为试验组和对照组,各46例。对照组给予阿替普酶治疗,试验组在对照组基础上使用前列地尔治疗,比较两组治疗前后的神经功能(NIHSS评分)、大脑中动脉和大脑前动脉血流速度、血清炎症因子(CRP、TNF-α、IL-6)、生活自理能力(Barthel指数评分)及不良反应发生情况。结果:治疗后,试验组NIHSS评分低于对照组(P<0.05);治疗后,试验组大脑中动脉、大脑前动脉血流速度均大于对照组(P<0.05);治疗后,试验组CRP、TNF-α、IL-6水平均低于对照组(P<0.05);治疗后,试验组Barthel指数评分高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:前列地尔辅助治疗急性脑梗死患者,能显著提高患者的神经功能,改善患者脑部血流,减轻炎症,提高患者生活自理能力,值得临床推广应用。
Objective:To explore the clinical effect of Alprostadil adjuvant therapy on acute cerebral infarction.Method:A total of 92 patients with acute cerebral infarction diagnosed and treated in our hospital from February 2016 to February 2018 were selected.According to the random number table method,they were divided into experimental group and control group,46 cases in each group.The control group was treated with Alteplase,while experimental group was treated with Alprostadil on the basis of control group.Neurological function(NIHSS score),blood flow velocity of middle cerebral artery and anterior cerebral artery,serum inflammatory factors(CRP,TNF-α,IL-6),self-care ability(Barthel index score)before and after treatment,and adverse reactions between two groups were compared.Result:After treatment,the NIHSS score of experimental group was lower than that of control group(P<0.05).After treatment,the blood flow velocity of middle cerebral artery and anterior cerebral artery in experimental group were higher than those of control group(P<0.05).After treatment,the levels of CRP,TNF-α,IL-6 in experimental group were lower than those of control group(P<0.05).After treatment,the Barthel index score of experimental group was higher than that of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Alprostadil adjuvant treatment of acute cerebral infarction can significantly improve the neurological function,improve the cerebral blood flow,reduce inflammation and improve the self-care ability of patients,it is worthy of clinical application.
作者
王伊红
WANG Yihong(Jiamusi Central Hospital,Jiamusi 154002,China)
出处
《中国医学创新》
CAS
2019年第20期52-55,共4页
Medical Innovation of China
关键词
前列地尔
阿替普酶
急性脑梗死
Alprostadil
Alteplase
Acute cerebral infarction